June Lee is fundraising a new venture built around an in-licensed clinical-stage Chinese asset — a pattern that has produced the fastest US-listed biotechs of the past 24 months (Structure Therapeutics, Nuvation Bio, LaunchBio-anchored spinouts). She is the founder and CEO of Alumis / Esker Therapeutics; before that she was EVP / CDO / COO at MyoKardia (BMS $13.1B, 2020), and before that Professor of Medicine at UCSF running translational research and the Catalyst Program.
SH is being brought in extremely early — the July 1 call was the initial thesis conversation and the newco has not yet been incorporated. The right SH stance is to keep the seat warm, learn about the asset as it becomes shareable, and be a first-money candidate when the round forms. June's track record is one of the strongest in biotech and she rarely re-uses SH as a first-money source without a clear path.
Chinese in-licensing has become the single fastest-growing biotech deal source for US-listed spinouts (Web) — Structure Therapeutics, Nuvation Bio, and multiple Third Rock / RA Capital spinouts have used this playbook to reach the clinic 3–5 years faster than de-novo discovery. TAM depends entirely on the indication and asset, which are not yet public.
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| June.Lee Newco | Chinese in-license to US clinical development, June Lee-led | Pre-Round | — |
| Structure Therapeutics | GLP-1 obesity asset in-licensed from ShouTi | Public, NASDAQ:GPCR | Same playbook; different asset |
| Nuvation Bio | Multi-asset oncology + China in-license | Public | Same playbook; different portfolio |
| Any pending Q3 2026 Series A biotech in-license | — | Various | Competitive with the venture creators (RA, Third Rock, Foresite) who play this space heavily |
Moat: The moat is executional — June Lee has run the clinical-development function through a $13B outcome (MyoKardia / BMS). In-license diligence, IND assembly, and phase transitions are her operating specialty. The asset choice determines the market; the operator determines execution.
Pre-formation. Traction signal is June's operating track record and the asset selection thesis — both of which are pre-disclosure at this stage.
Comparable outcomes: MyoKardia (BMS, $13.1B, 2020) — the founder's own prior venture. Structure Therapeutics IPO (2023, ~$1B valuation on debut). BeiGene's in-licensing model. In-licensed clinical-stage assets typically reach an inflection (POC, breakthrough designation, or IPO) 12–24 months post-Series A, which sets up the exit path.
First conversation with June about the newco. Broadly discussed the in-licensing thesis and the operator model; asset detail is not yet shareable.